Results 71 to 80 of about 30,645 (194)
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B [PDF]
During the course of chronic hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) seroconversion to its antibody (anti-HBe) often coincides with normalization of liver biochemical test and clinical remission, but data regarding long-term outcome after spontaneous seroconversion are still scarce.
Yao-Shih, Hsu +6 more
openaire +2 more sources
Estimated probabilities for each drug to be ranked as HBeAg seroconversion after a 2-year treatment.
Estimated probabilities for each drug to be ranked as HBeAg seroconversion after a 2-year treatment.
Lin Cao (294505) +3 more
core +1 more source
Soluble immune markers in the different phases of chronic hepatitis B virus infection
Chronic hepatitis B virus (HBV) infection may follow four different consecutive phases, which are defined by virology as well as biochemical markers and differ in terms of prognosis and need for antiviral treatment. Currently, host responses reflected by
Steffen B. Wiegand +12 more
doaj +1 more source
Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan
Hepatitis B is a viral liver infection that can become chronic, increasing the risk of developing liver cancer and liver failure. Because current treatments rarely cure these problems, researchers are now focusing on a functional cure in which the virus becomes undetectable in blood and stays that way, even after the treatment ends.
Yutaka Handa +2 more
wiley +1 more source
Frequency-dependent selection drives HBeAg seroconversion in chronic hepatitis B virus infection [PDF]
HBeAg seroconversion is an important stage in the evolution of a chronic hepatitis B virus (HBV) infection that usually leads to control of viral replication and a reduced risk for liver cirrhosis and cancer. Since current therapies for the HBV-associated liver inflammation that is known as chronic hepatitis B (CHB).
Warner, Brook G. +2 more
openaire +2 more sources
Continuous variables: median (25th, 75th percentiles); categorical variables: numbers(percentages)IFN: interferon; ALT: alanine aminotransferase; ULN: upper limit of normal; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigenFactors ...
Jee-Fu Huang (292609) +10 more
core +1 more source
ABSTRACT Antiviral treatment for chronic HBV infection in the “high‐replicative low‐inflammatory” phase has not been widely recommended. This study aimed to evaluate the safety and efficacy of antiviral therapy in this patient population and analyze peripheral immunological characteristics in relation to treatment response.
Qiumin Luo +12 more
wiley +1 more source
Chronic hepatitis B patient (CHB) presents a challenge due to immune tolerance toward HBV surface antigen (HBsAg). This study aimed to achieve a functional cure by disrupting HBV tolerance through immunotherapy. CHB received standard NA therapy, or NA combined with IFN‐α, while a third group received the THRIL‐GM‐Vac regimen.
Shuang Geng +16 more
wiley +1 more source
OBJECTIVES: The aim of this study was to compare the virological and biochemical relapse rates in Asian chronic hepatitis B patients with lamivudine-induced hepatitis B e antigen (HBeAg) seroconversion, between those who stopped therapy after HBeAg ...
Yuen, J +6 more
core +1 more source
Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression
Serum HBV RNA levels at viral suppression predict HCC development in nucleos(t)ide analogue‐treated patients with chronic hepatitis B, outperforming Hepatitis B core‐related antigen alone. ABSTRACT Background Despite achieving undetectable hepatitis B virus (HBV) DNA levels with nucleos(t)ide analogue (NA) therapy, patients with chronic hepatitis B ...
Takashi Kumada +6 more
wiley +1 more source

